Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.
- Home |
- Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
- April 20, 2026
Recent Posts
- GeoPark awarded Corralera Noreste block in Vaca Muerta bid round
- Tight product supplies lift US summer refinery utilization to highest level since 1998
- Valero wraps St. Charles FCC project, reports record earnings
- EIA: US crude oil inventories down 3.1 million bbl
- Adura gets NSTA consent to develop Jackdaw North Sea gas field
